Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Suppression of inflammatory cytokine secretion by an NF-ĸB inhibitor DHMEQ in nasal polyps fibroblasts.

Valera FC, Umezawa K, Brassesco MS, Castro-Gamero AM, Queiroz RG, Scrideli CA, Tone LG, Anselmo-Lima WT.

Cell Physiol Biochem. 2012;30(1):13-22. doi: 10.1159/000339042. Epub 2012 Jun 5.

2.

Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, prevents inflammatory injury induced by interferon-gamma and histamine in NCTC 2544 keratinocytes.

Cardile V, Libra M, Caggia S, Frasca G, Umezawa K, Stivala F, Mazzarino MC, Bevelacqua Y, Coco M, Malaponte G.

Clin Exp Pharmacol Physiol. 2010 Jul;37(7):679-83. doi: 10.1111/j.1440-1681.2010.05375.x. Epub 2010 Mar 12.

PMID:
20337659
3.

In vitro effect of glucocorticoids on nasal polyps.

Valera F, Brassesco MS, Castro-Gamero AM, Cortez MA, Queiroz RG, Tone LG, Anselmo-Lima WT.

Braz J Otorhinolaryngol. 2011 Sep-Oct;77(5):605-10. English, Portuguese.

4.

Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1β in human corneal fibroblasts.

Inokawa S, Watanabe T, Keino H, Sato Y, Hirakata A, Okada AA, Fukuda K, Fukushima A, Umezawa K.

Graefes Arch Clin Exp Ophthalmol. 2015 Apr;253(4):557-63. doi: 10.1007/s00417-014-2879-9. Epub 2014 Dec 18.

PMID:
25519802
5.

Fluticasone propionate downregulates nasal fibroblast functions involved in airway inflammation and remodeling.

Silvestri M, Sabatini F, Scarso L, Cordone A, Dasic G, Rossi GA.

Int Arch Allergy Immunol. 2002 May;128(1):51-8.

PMID:
12037401
6.

Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF-kappaB inhibitor DHMEQ under flow.

Ohno O, Shima Y, Ikeda Y, Sakurai K, Watanabe K, Kawai Y, Umezawa K.

Oncol Res. 2005;15(4):189-97.

PMID:
17822279
7.

Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin.

Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K.

J Biol Chem. 2002 Jul 5;277(27):24625-30. Epub 2002 Apr 30.

8.

Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF-kappaB inhibitor.

Takatsuna H, Morita S, Nagatsu T, Sawada M, Umezawa K.

Biomed Pharmacother. 2005 Jul;59(6):318-22.

PMID:
15932789
9.

Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.

Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M, Umezawa K.

Clin Cancer Res. 2005 Feb 1;11(3):1287-93.

10.

Effects of a novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines.

Ruan HY, Masuda M, Ito A, Umezawa K, Nakashima T, Yasumatsu R, Kuratomi Y, Yamamoto T, Weinstein IB, Komune S.

Head Neck. 2006 Feb;28(2):158-65.

PMID:
16355386
11.

Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.

Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, Yamashiro K, Inoue M, Tsubota K, Umezawa K, Ishida S.

Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4342-50.

PMID:
17724226
12.

Dehydroxymethylepoxyquinomicin inhibits expression and production of inflammatory mediators in interleukin-1beta-induced human chondrocytes.

Cardile V, Frasca G, Libra M, Caggia S, Umezawa K, Panico A, Malaponte G.

Cell Physiol Biochem. 2010;25(4-5):543-50. doi: 10.1159/000303058. Epub 2010 Mar 23.

13.

Differential expression of adhesion molecules by sinonasal fibroblasts among control and chronic rhinosinusitis patients.

Oyer SL, Nagel W, Mulligan JK.

Am J Rhinol Allergy. 2013 Sep-Oct;27(5):381-6. doi: 10.2500/ajra.2013.27.3934.

PMID:
24119601
14.

Effect of intranasal fluticasone on cellular infiltration, endothelial adhesion molecule expression, and proinflammatory cytokine mRNA in nasal polyp disease.

Hamilos DL, Thawley SE, Kramper MA, Kamil A, Hamid QA.

J Allergy Clin Immunol. 1999 Jan;103(1 Pt 1):79-87.

PMID:
9893189
15.

Effect of a small molecule inhibitor of nuclear factor-kappaB nuclear translocation in a murine model of arthritis and cultured human synovial cells.

Wakamatsu K, Nanki T, Miyasaka N, Umezawa K, Kubota T.

Arthritis Res Ther. 2005;7(6):R1348-59. Epub 2005 Sep 30.

16.

DHMEQ, a novel NF-kappaB inhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells.

Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, Kawashimo H, Goto T, Taura N, Ichikawa T, Hamasaki K, Nakao K, Umezawa K, Eguchi K.

Int J Oncol. 2006 Sep;29(3):713-9.

PMID:
16865289
17.

The histamine-induced enhanced expression of vascular cell adhesion molecule-1 by nasal polyp-derived fibroblasts is inhibited by levocetirizine.

Petecchia L, Serpero L, Silvestri M, Sabatini F, Scarso L, Rossi GA.

Am J Rhinol. 2006 Sep-Oct;20(5):445-9.

PMID:
17063735
18.

Molecular design and biological activities of NF-kappaB inhibitors.

Umezawa K, Chaicharoenpong C.

Mol Cells. 2002 Oct 31;14(2):163-7. Review.

19.

Effects of DHMEQ, a novel nuclear factor-kappab inhibitor, on beta cell dysfunction in INS-1 cells.

Saisho Y, Hirose H, Horimai C, Miyashita K, Takei I, Umezawa K, Itoh H.

Endocr J. 2008 May;55(2):433-8. Epub 2008 Apr 2.

20.

Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages.

Suzuki E, Sugiyama C, Umezawa K.

Biomed Pharmacother. 2009 Jun;63(5):351-8. doi: 10.1016/j.biopha.2008.05.003. Epub 2008 Jun 20.

PMID:
18635336

Supplemental Content

Support Center